AU2015329999B2 - 17a,21-diesters of cortexolone for use in the treatment of tumors - Google Patents

17a,21-diesters of cortexolone for use in the treatment of tumors Download PDF

Info

Publication number
AU2015329999B2
AU2015329999B2 AU2015329999A AU2015329999A AU2015329999B2 AU 2015329999 B2 AU2015329999 B2 AU 2015329999B2 AU 2015329999 A AU2015329999 A AU 2015329999A AU 2015329999 A AU2015329999 A AU 2015329999A AU 2015329999 B2 AU2015329999 B2 AU 2015329999B2
Authority
AU
Australia
Prior art keywords
cortexolone
formula
pharmaceutical compositions
active ingredients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015329999A
Other languages
English (en)
Other versions
AU2015329999A1 (en
Inventor
Mara Gerloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of AU2015329999A1 publication Critical patent/AU2015329999A1/en
Application granted granted Critical
Publication of AU2015329999B2 publication Critical patent/AU2015329999B2/en
Priority to AU2020201446A priority Critical patent/AU2020201446B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2015329999A 2014-10-08 2015-10-07 17a,21-diesters of cortexolone for use in the treatment of tumors Active AU2015329999B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201446A AU2020201446B2 (en) 2014-10-08 2020-02-27 17a,21-diesters of cortexolone for use in the treatment of tumors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188063.3 2014-10-08
EP14188063.3A EP3006453A1 (en) 2014-10-08 2014-10-08 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
PCT/EP2015/073172 WO2016055533A1 (en) 2014-10-08 2015-10-07 17a,21-diesters of cortexolone for use in the treatment of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201446A Division AU2020201446B2 (en) 2014-10-08 2020-02-27 17a,21-diesters of cortexolone for use in the treatment of tumors

Publications (2)

Publication Number Publication Date
AU2015329999A1 AU2015329999A1 (en) 2017-04-06
AU2015329999B2 true AU2015329999B2 (en) 2020-01-23

Family

ID=51687868

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015329999A Active AU2015329999B2 (en) 2014-10-08 2015-10-07 17a,21-diesters of cortexolone for use in the treatment of tumors
AU2015330003A Abandoned AU2015330003A1 (en) 2014-10-08 2015-10-07 Cortexolone 17alpha-benzoate for use in the treatment of tumours
AU2020201446A Active AU2020201446B2 (en) 2014-10-08 2020-02-27 17a,21-diesters of cortexolone for use in the treatment of tumors

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2015330003A Abandoned AU2015330003A1 (en) 2014-10-08 2015-10-07 Cortexolone 17alpha-benzoate for use in the treatment of tumours
AU2020201446A Active AU2020201446B2 (en) 2014-10-08 2020-02-27 17a,21-diesters of cortexolone for use in the treatment of tumors

Country Status (23)

Country Link
US (8) US10183030B2 (enExample)
EP (4) EP3006453A1 (enExample)
JP (5) JP6503057B2 (enExample)
KR (5) KR102520411B1 (enExample)
CN (5) CN111285913B (enExample)
AU (3) AU2015329999B2 (enExample)
BR (2) BR112017007078A2 (enExample)
CA (3) CA2962746A1 (enExample)
DK (2) DK3456330T3 (enExample)
ES (3) ES2806094T3 (enExample)
HR (2) HRP20190194T1 (enExample)
HU (2) HUE055143T2 (enExample)
IL (3) IL272095B2 (enExample)
LT (2) LT3204400T (enExample)
MX (3) MX366294B (enExample)
PL (2) PL3204400T3 (enExample)
PT (2) PT3204400T (enExample)
RS (2) RS62147B1 (enExample)
RU (2) RU2712950C2 (enExample)
SI (2) SI3204400T1 (enExample)
TR (1) TR201901422T4 (enExample)
WO (2) WO2016055537A1 (enExample)
ZA (2) ZA201702209B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN110698527B (zh) * 2019-11-19 2022-08-26 湖南新合新生物医药有限公司 一种高纯度氢化可的松-17-戊酸酯的制备方法
CN112028956A (zh) * 2020-09-10 2020-12-04 那路新 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用
WO2023088308A1 (zh) * 2021-11-16 2023-05-25 石家庄迪斯凯威医药科技有限公司 一种具有抗耐药性的抗菌化合物
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3530038A (en) * 1966-04-25 1970-09-22 Koninklijke Gist Spiritus Process for preparation of trihydroxy steroids
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101743316A (zh) * 2007-08-03 2010-06-16 科斯莫股份公司 用于获得11-脱氧皮醇的17α-单酯和/或其9,11-脱氢衍生物的酶法
WO2011151252A2 (en) * 2010-06-01 2011-12-08 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject
WO2012129305A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE619180A (fr) * 1961-06-24 1962-12-20 Vismara Francesco Spa 17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation
DE1195748B (de) * 1961-06-24 1965-07-01 Vismara Francesco Spa Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
DE2748442C3 (de) 1977-10-26 1981-08-27 Schering Ag Berlin Und Bergkamen, 1000 Berlin 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel
EP0001737B1 (de) * 1977-10-26 1981-01-07 Schering Aktiengesellschaft 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung
ATE12237T1 (de) * 1980-12-23 1985-04-15 Schering Ag Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung.
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4920216A (en) * 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
WO1990009394A2 (en) 1989-02-07 1990-08-23 The Upjohn Company Dehalogenation of organic compounds using tin or lead
DE4121484A1 (de) 1991-06-26 1993-01-07 Schering Ag Verfahren zur herstellung von 6-methylensteroiden
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AU1770901A (en) 2000-11-16 2002-05-27 Alcon Lab Inc Combination therapy for lowering and controlling intraocular pressure
ITMI20011762A1 (it) * 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
ITMI20051695A1 (it) * 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
DE102006059063A1 (de) 2005-12-24 2007-06-28 Bayer Healthcare Ag Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
CN101397317A (zh) 2007-09-27 2009-04-01 天津药业研究院有限公司 一种新型硝酸酯类甾体化合物
JP2010515777A (ja) 2008-03-18 2010-05-13 シコール インコーポレイティド 空気感受性ステロイドの精製
RU2506974C1 (ru) 2012-11-06 2014-02-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения первично нерезектабельного рака легкого
CA3105575A1 (en) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3530038A (en) * 1966-04-25 1970-09-22 Koninklijke Gist Spiritus Process for preparation of trihydroxy steroids
CN101743316A (zh) * 2007-08-03 2010-06-16 科斯莫股份公司 用于获得11-脱氧皮醇的17α-单酯和/或其9,11-脱氢衍生物的酶法
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2011151252A2 (en) * 2010-06-01 2011-12-08 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject
WO2012129305A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUTLER, GORDON B., JR. ET AL, "11-Deoxycortisol: a glucocorticoid antagonist in vivo", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1979:469056, URL: STN *
FERRABOSCHI P ET AL, "Lipase-catalyzed preparation of corticosteroid 17alpha-esters endowed with antiandrogenic activity", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 49, no. 31, 2008, pages 4610 - 4612 *
JJ KEATING ET AL, "A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma", BRITISH JOURNAL OF CANCER, (1989-11-01), vol. 60, no. 5, doi:10.1038/bjc.1989.361, ISSN 0007-0920, pages 789 792 *
PATRIZIA FERRABOSCHI ET AL, MEDCHEMCOMM, 2014, vol. 5, no. 7, pages 904 - 914 *
PETERSON, R. E., "Biliary excretion of neutral steroids in man", DATABASE CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1966:87023, URL: STN *

Also Published As

Publication number Publication date
US20190091240A1 (en) 2019-03-28
SI3204400T1 (sl) 2019-04-30
MX2019008063A (es) 2019-09-11
CN115671114A (zh) 2023-02-03
RU2712752C2 (ru) 2020-01-31
PL3456330T3 (pl) 2021-11-15
AU2015330003A1 (en) 2017-04-13
RU2712950C2 (ru) 2020-02-03
RU2017115773A3 (enExample) 2019-03-15
KR20170063799A (ko) 2017-06-08
US20240277731A1 (en) 2024-08-22
KR20170063821A (ko) 2017-06-08
RU2017115773A (ru) 2018-11-15
US20230128438A1 (en) 2023-04-27
MX2017004661A (es) 2017-10-16
KR20210012047A (ko) 2021-02-02
KR102712584B1 (ko) 2024-10-04
CA2960928C (en) 2023-10-31
JP7028809B2 (ja) 2022-03-02
US20200215080A1 (en) 2020-07-09
BR112017007078A2 (pt) 2017-12-26
CA2962746A1 (en) 2016-04-14
US10646497B2 (en) 2020-05-12
CA3160391A1 (en) 2016-04-14
US11712443B2 (en) 2023-08-01
WO2016055537A1 (en) 2016-04-14
CA2960928A1 (en) 2016-04-14
ES2806094T3 (es) 2021-02-16
ES2882223T3 (es) 2021-12-01
CN111285913A (zh) 2020-06-16
AU2015329999A1 (en) 2017-04-06
LT3204400T (lt) 2019-04-10
SI3456330T1 (sl) 2021-09-30
BR112017007076B1 (pt) 2023-12-19
IL251028B (en) 2020-01-30
MX2017004660A (es) 2017-10-16
AU2020201446A1 (en) 2020-05-14
PT3204400T (pt) 2019-02-25
CN107074905B (zh) 2019-08-09
JP2019070033A (ja) 2019-05-09
IL272095A (en) 2020-03-31
US20190175618A1 (en) 2019-06-13
JP2017530184A (ja) 2017-10-12
PL3204400T3 (pl) 2019-05-31
CN107074905A (zh) 2017-08-18
ES2713699T3 (es) 2019-05-23
MX385557B (es) 2025-03-18
RU2020102939A (ru) 2020-05-20
CN111285913B (zh) 2023-01-10
KR102520411B1 (ko) 2023-04-11
LT3456330T (lt) 2021-08-10
JP6735739B2 (ja) 2020-08-05
US20210299145A1 (en) 2021-09-30
US20170360806A1 (en) 2017-12-21
IL251371A0 (en) 2017-05-29
ZA201902320B (en) 2022-11-30
MX366294B (es) 2019-07-04
CN116102604A (zh) 2023-05-12
HUE041503T2 (hu) 2019-05-28
DK3204400T3 (en) 2019-03-04
JP2017530171A (ja) 2017-10-12
US20170304318A1 (en) 2017-10-26
TR201901422T4 (tr) 2019-02-21
CN107001406B (zh) 2020-03-27
PT3456330T (pt) 2021-07-13
RU2017115771A3 (enExample) 2019-03-11
BR112017007076A2 (pt) 2017-12-26
EP3204400B1 (en) 2018-12-12
WO2016055533A1 (en) 2016-04-14
EP3006453A1 (en) 2016-04-13
EP3204012B1 (en) 2020-06-03
JP6503057B2 (ja) 2019-04-17
CA3160391C (en) 2024-06-25
CN107001406A (zh) 2017-08-01
HRP20190194T1 (hr) 2019-04-19
KR102248983B1 (ko) 2021-05-10
HUE055143T2 (hu) 2021-11-29
HRP20211177T1 (hr) 2021-10-29
EP3456330A1 (en) 2019-03-20
US10183030B2 (en) 2019-01-22
IL272095B2 (en) 2023-04-01
AU2020201446B2 (en) 2021-03-18
EP3204400A1 (en) 2017-08-16
RU2017115771A (ru) 2018-11-12
IL272095B (en) 2022-12-01
US11986484B2 (en) 2024-05-21
RS58607B1 (sr) 2019-05-31
EP3204012A1 (en) 2017-08-16
US10231980B2 (en) 2019-03-19
ZA201702209B (en) 2019-08-28
US10993949B2 (en) 2021-05-04
KR20240149968A (ko) 2024-10-15
DK3456330T3 (da) 2021-07-26
RS62147B1 (sr) 2021-08-31
KR20230052990A (ko) 2023-04-20
IL251028A0 (en) 2017-04-30
EP3456330B1 (en) 2021-05-19
JP2020143140A (ja) 2020-09-10
JP2021046418A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
AU2015329999B2 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
TW201613901A (en) New compounds
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
NZ752526A (en) Pyrrolobenzodiazepine conjugates
EA033689B9 (ru) Ингибиторы g12c kras
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12016500024A1 (en) Bromodomain inhibitor
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
BR112016022062A8 (pt) combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX2018003563A (es) Nuevos compuestos.
MX382832B (es) Benzimidazoles sustituidos, su preparación y su uso como productos farmacéuticos.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
WO2019209232A3 (en) The use of terpenic coumarine derivative molecules in the treatment of cancer disease
HK1239539A1 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumours
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)